VFLO Medical Announces Strategic Partnership with Inari Medical and Closes $80 Million Series B Financing

December 3, 2024, Shanghai, China. VFLO Medical ("Jitong Medical"), a peripheral vascular innovative medical device company, announced a strategic partnership with Nasdaq-listed Inari Medical ("Inari"). Under the agreement, Jitong Medical has obtained the distribution rights for a series of Inari’s innovative medical device products, including ClotTriever and FlowTriever, in the Greater China region, as well as the rights to localize production using Inari’s technology and sell these products within the region. Meanwhile, Jitong Medical announced the completion of an $80 million Series B financing round, co-invested by prominent institutions such as 6 Dimensions Capital and its dollar fund 120 Capital, a large family office, Hefei State-owned Assets Holding Company Limited, Hefei High Tech Venture Capital Management Partnership (L.P.), and University of Science and Technology Silicon Valley Service Platform (Anhui) Co., Ltd. The funds raised will support the clinical development and commercialization of multiple collaborative and self-developed innovative pipelines in the peripheral interventional field by Jitong Medical, aiming to meet the significant clinical needs in China's peripheral vascular sector and bring more cutting-edge solutions for the treatment of peripheral vascular diseases.

In the future, VFLO Medical will fully cooperate with Inari Medical to carry out the registration and promotion of ClotTriever, FlowTriever, and other series of products in the Greater China region. ClotTriever is an innovative mechanical thrombectomy device specifically developed for deep vein thrombosis, which received FDA approval in the United States in 2017; FlowTriever is the world's first mechanical thrombectomy system for the treatment of pulmonary embolism, which received FDA approval in the United States in 2015. To date, ClotTriever and FlowTriever have successfully treated more than 150,000 patients worldwide. Currently, both products have entered the special review process for innovative medical devices by the National Medical Products Administration.

VFLO Medical Management TeamStated: "The company team has been deeply engaged in China's peripheral vascular and cardiovascular intervention industry for many years, possessing abundant industrial resources and experience. This strategic cooperation with Inari combines globally leading innovative products, excellent clinical trial data and real-world experience, as well as the professional teams of both parties. In the future, VFLO Medical will continue to provide high-quality solutions for peripheral vascular disease interventional treatment to doctors and patients in China through a dual-driven approach of product introduction and independent research and development."

Inari Medical Management TeamSaid: "This collaboration allows different types of patients and medical institutions in China to benefit from Inari's innovative products. We are excited to have reached a long-term strategic partnership with 6 Dimensions Capital and 120 Capital. Through VFLO Medical, we will continuously introduce Inari's products into the Greater China region, strengthen the vascular intervention market, and bring more benefits to patients."

6 Dimensions Capital Management Team"We believe that VFLO Medical will become a leader in China's peripheral vascular treatment field. The strategic cooperation with Inari Medical will bring transformative impact to the treatment of venous diseases in China. Moreover, VFLO Medical has a series of innovative products independently developed with the aim of becoming the gold standard for peripheral vascular treatments. Like Inari, we are passionate about advancing medical technology innovation and firmly believe that our collaboration will bring significant positive changes to the lives of patients with vascular diseases in China."

VFLO Medical is a medical device company headquartered in China, established in 2021 by 6 Dimensions Capital, 120 Capital, and an experienced professional team. It aims to create a leading medical device platform, focusing on providing innovative vascular treatment solutions for patients in China and around the world.

"Patients First, Long-term Vision, Care for Each Other" – These are the core values of Inari Medical. Inari Medical is committed to addressing unmet clinical needs with innovative and leading-edge solutions, providing patients with life-changing treatment options. Focused on products designed for specific diseases, Inari Medical continuously enhances patient clinical outcomes through professional education, clinical research, and project development. The company aims to establish its innovative products and solutions as the gold standard in venous disease treatment. For more information, please visit:www.inarimedical.com。

6 Dimensions Capital and its USD fund, 120 Capital, is a global company focused on healthcare investment. It currently has offices in Boston, San Francisco, Hong Kong, and Shanghai. The company invests in early- and growth-stage healthcare companies in regions such as China, Europe, the U.S., and Israel, empowering entrepreneurs to build innovative healthcare businesses that benefit patients worldwide.